Comprehensive Income (Loss), Net of Tax, Attributable to Parent of Inhibikase Therapeutics, Inc. from 30 Jun 2022 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
Summary
Inhibikase Therapeutics, Inc. quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent in USD history and change rate from 30 Jun 2022 to 30 Sep 2024.
  • Inhibikase Therapeutics, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent for the quarter ending 30 Sep 2024 was $5,775,288, a 26% decline year-over-year.
Source SEC data
View on sec.gov
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Quarterly (USD)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent, YoY Quarterly Change (%)

Inhibikase Therapeutics, Inc. Quarterly Comprehensive Income (Loss), Net of Tax, Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $5,775,288 -$1,181,660 -26% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2024 2024 Q3
Q2 2024 $4,958,832 +$986,670 +17% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q3 2023 $4,593,628 -$125,893 -2.8% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 $5,945,502 -$1,305,563 -28% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2023 2023 Q2
Q3 2022 $4,467,735 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $4,639,939 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
* An asterisk sign (*) next to the value indicates that the value is likely invalid.